0000000000242476

AUTHOR

A Cascio

showing 5 related works from this author

Antibiotic treatment of infections caused by carbapenem-resistant Gram-negative bacilli: an international ESCMID cross-sectional survey among infecti…

2018

ESGAP, ESGBIS, ESGIE and the CRGNB treatment survey study group.

0301 basic medicineAcinetobacter baumanniiCarbapenemAntibioticsDrug ResistanceDrug resistanceTigecyclineAcinetobacter baumannii; Carbapenem; Carbapenem-resistant Gram-negative bacilli; Combination therapy; Enterobacteriaceae; Polymyxin; Pseudomonas aeruginosa; SurveyPolymyxin0302 clinical medicineSurveys and Questionnairespolycyclic compounds030212 general & internal medicineAcinetobacter baumannii; Carbapenem; Carbapenem-resistant Gram-negative bacilli; Combination therapy; Enterobacteriaceae; Polymyxin; Pseudomonas aeruginosa; Survey; Anti-Bacterial Agents; Carbapenems; Cross Infection; Cross-Sectional Studies; Drug Resistance Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Hospitals; Humans; Microbial Sensitivity Tests; Surveys and QuestionnairesSurveyCarbapenemAcinetobacter baumannii; Carbapenem; Carbapenem-resistant Gram-negative bacilli; Combination therapy; Enterobacteriaceae; Polymyxin; Pseudomonas aeruginosa; Survey; Anti-Bacterial Agents; Carbapenems; Cross Infection; Cross-Sectional Studies; Drug Resistance Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Hospitals; Humans; Microbial Sensitivity Tests; Surveys and Questionnaires; Microbiology (medical); Infectious DiseasesCross InfectionbiologyMicrobial Sensitivity TestCarbapenem-resistant Gram-negative bacilliBacterialantibiotic management carbapenem-resistant Gram-negative bacteriaGeneral MedicineHospitals3. Good healthAcinetobacter baumanniiAnti-Bacterial AgentsInfectious DiseasesPseudomonas aeruginosamedicine.drugHumanMicrobiology (medical)medicine.medical_specialtymedicine.drug_class030106 microbiologyMicrobial Sensitivity TestsFosfomycincarbapenem-resistant Gram-negative bacteria03 medical and health sciencesHospitalEnterobacteriaceaeInternal medicineAnti-Bacterial AgentDrug Resistance BacterialGram-Negative BacteriamedicineGram-Negative Bacterial InfectionHumansCombination therapyCross-Sectional Studiebusiness.industrybiochemical phenomena metabolism and nutritionbiology.organism_classificationbacterial infections and mycosesCross-Sectional StudiesCarbapenemsInfectious disease (medical specialty)Carbapenem-resistant gram-negative bacilli[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieantibiotic managementbusinessGram-Negative Bacterial InfectionsRifampicin
researchProduct

Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline viro-immunological status and outcome in patients under first-line ART

2018

Objectives We evaluated the association between pre-ART HIV DNA and HIV-infected participant characteristics at baseline as well as with their response to first-line ART. Methods Four hundred and thirty-three patients from the ICONA cohort, starting first-line ART after the year 2000, were analysed. Pre-ART HIV DNA was quantified with the modified COBAS TaqMan HIV-1 Test and normalized by CD4+ T cells. Linear correlation between pre-ART HIV DNA and other continuous markers (HIV RNA, CD4 count, markers of inflammation and coagulation) at baseline was evaluated by means of Pearson correlation coefficient and a linear regression model. Survival analyses and Cox regression models were used to s…

0301 basic medicineOncologyCD4-Positive T-LymphocytesMaleHIV InfectionsSettore MED/07chemistry.chemical_compoundHIV InfectionPharmacology (medical)ViralProspective StudiesProspective cohort studyAntiinfective agentAdult; Anti-Retroviral Agents; CD4-Positive T-Lymphocytes; DNA Viral; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Prospective Studies; Survival Analysis; Treatment Outcome; Viral LoadMiddle AgedViral LoadvirologyHIV CD4Stavudinemedicine.anatomical_structureInfectious DiseasesTreatment Outcomehiv-1 t-lymphocytes virology blood hiv rna hiv dnaAnti-Retroviral AgentsCD4-Positive T-Lymphocyteblood hiv rnaCohorthiv dnaFemaleSurvival AnalysiViral loadARTHumanMicrobiology (medical)Adultmedicine.medical_specialtyAntiretroviral Therapy CD4 Lymphocyte Count StavudineT cellAntiretroviral TherapySettore MED/17 - MALATTIE INFETTIVENO03 medical and health sciencesInternal medicinemedicineHumanst-lymphocytesSurvival analysisPharmacologybusiness.industryProportional hazards modelHIVDNASurvival AnalysisCD4 Lymphocyte CountProspective Studie030104 developmental biologychemistryDNA ViralHIV-1Anti-Retroviral AgentbusinessDNA
researchProduct

The effect of L-thyroxine on the metamorphosis of Ascidia malaca

1981

Larvae of Ascidia malaca, both before and after hatching, were treated with L-thyroxine solutions. The effect of the thyroid hormone was to induce the onset of metamorphosis and then to cause the rate at which body reorganization occurred to increase. In treated larvae the resorption of the tail occurred only few hours after hatching, and a beating heart appeared form 10 to 15 h earlier than in the control larvae. These results are discussed in the context of a probable relationship between the occurrence of a hormonal metamorphic factor and the button cells of the trunk.

medicine.medical_specialtyanimal structuresHistologygenetic structuresmedia_common.quotation_subjectContext (language use)Pathology and Forensic MedicineInternal medicinemedicineAnimalsUrochordataMetamorphosismedia_commonLarvabiologyHatchingfungiThyroidMetamorphosis BiologicalCell Biologybiology.organism_classificationResorptionAscidiaThyroxineEndocrinologymedicine.anatomical_structureLarvaHormoneCell and Tissue Research
researchProduct

Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort

2019

AbstractObjectivesTo evaluate the incidence and risk factors for liver enzyme elevations (LEE) in patients initiating first-line ART in the ICONA prospective observational cohort, between June 2009 and December 2017.Patients and methodsIn total, 6575 ART-naive patients were selected, initiating two NRTIs with the third drug being a boosted PI (n=2436; 37.0%), an NNRTI (n=2384; 36.3%) or an integrase strand transfer inhibitor (INSTI) (n=1755; 26.7%). HBV surface antigen and HCV RNA were detected in 3.9% and 5.8% of the study population. Inverse probability weighted Cox regression analysis was used to calculate the HRs, according to first-line regimen, for LEE, defined as ALT or AST increases…

0301 basic medicineMaleIntegrase inhibitorHepatitis B Surface AntigenHIV Infections0302 clinical medicineRisk Factorshivh epatitis c rna surface antigens follow-up homosexuality integrase inhibitors hepatitis b virus hepatitis b virus measurement hiv infections hepatotoxicity hepatitis c virus coinfection nucleoside reverse transcriptase inhibitors non-nucleoside reverse transcriptase inhibitors cox proportional hazards models baseline value liver enzyme raltegravirPharmacology (medical)HIV Infection030212 general & internal medicineProspective StudiesProspective cohort studyCoinfectionIncidence (epidemiology)Liver DiseaseIncidenceLiver Diseasesvirus diseasesHepatitis CMiddle AgedHepatitis CReverse Transcriptase InhibitorInfectious DiseasesCohortCoinfectionPopulation studyRegression AnalysisReverse Transcriptase InhibitorsFemalemedicine.drugHumanMicrobiology (medical)Adultmedicine.medical_specialtyAnti-HIV AgentsRegression AnalysiNO03 medical and health sciencesInternal medicinemedicineHumansHIV Integrase InhibitorsHIV Protease InhibitorPharmacologyHepatitis B Surface Antigensbusiness.industryAnti-HIV AgentHIV ARTHIV Protease Inhibitorsmedicine.diseaseRaltegravir030112 virologyHIV Integrase InhibitorProspective StudieHIV-1businessAdult Anti-HIV Agents Coinfection Female Hepatitis B Surface Antigens Hepatitis C HIV Infections HIV Integrase Inhibitors HIV Protease Inhibitors HIV-1 Humans Incidence Liver Diseases Male Middle Aged Prospective Studies Regression Analysis Reverse Transcriptase Inhibitors Risk Factors
researchProduct

Clinical recrudescence of chronic untreated P. malariae infection after BNT162b2 CoVID-19 vaccine

2022

We described a case of clinical reactivation of chronic P. malariae infection following CoVID-19 vaccination with BNT162b2 (Pifzer-Biontech CoVID-19 vaccine) in a 48-year old Italian man.The patient came to our attention for fever of unknown origin show a quartan pattern (every third day) associated to splenomegaly, the onset of the fever occurred one month after CoVID-19 vaccination with BNT162b2. P. malariae was diagnosed using CarestartTM malaria rapid test and Polymerase-Chain Reaction. Post-vaccine transient reduction of immune reactivity is described in literature, although the mechanism is unknown.(c) 2022 Published by Elsevier Ltd.CC_BY_NC_ND_4.0

Plasmodium malariaeInfectious DiseasesPlasmodium malariae.BNT162b2Chronic malariaBNT162b2; Chronic malaria; CoVID-19 vaccine; Malaria; Plasmodium malariaeCoVID-19 vaccineMalariaIDCases
researchProduct